Published date:Mar 28 2025

Journal Title: Sudan Journal of Medical Sciences

Issue title: Sudan JMS: Volume 20 (2025), Issue No. 1

Pages:81 - 90

DOI: 10.18502/sjms.v20i1.16175

Marvit Osman Widdatallah Omermarvatjazzar35@gmail.comDepartment of Pharmacology, Faculty of Pharmacy, University of Medical Sciences and Technology, Khartoum

Abdallah Omer AlkhawadDepartment of Pharmacology, Faculty of Pharmacy, University of Medical Sciences and Technology, Khartoum

Imad Taj EldinDepartment of Pharmacology, Faculty of Pharmacy, University of Gezira, Madani

Background: Adherence to the immunosuppressant agents is essential for reducing graft rejection. Several tools have been investigated to determine the adherence level of different medications, and the simplified medication adherence questionnaire (SMAQ) is considered one such tool, especially for tacrolimus. This study assesses adherence levels toward tacrolimus use in kidney transplant patients (KTPs).

Methods: This descriptive cross-sectional study was conducted at the Clinic of Nephrology, Ahmed-Gasim Hospital, Sudan, where a total of 166 KTPs responded to the questionnaire in the follow-up clinic, and those participants were treated with the immunosuppressant agent (tacrolimus). Statistical analysis was performed using the Statistical Package of Social Sciences (SPSS, version 27.0).

Results: Out of the 166 responders, 157 (94.6%) exerted a high level of adherence, and 9 (5.4%) were nonadherent. Among different factors related to the low adherence level, forgetfulness (n = 22; 13.3%) was a significant factor. Patient’s age (years), time since transplant (months), and the number of co-medications represented significant differences between the nonadherents and adherents (49.80 ± [10.592] vs 36.22 ± [11.434] P < 0.05), (9.80 ± [5.263] vs 4.27 ± [2.910] P < 0.05) ( 9(5.4%) vs 157 [94.6%] P < 0.05), respectively.

Conclusion: The adherence level of the studied participants was high. The nonadherence level was strongly associated with the patient’s age, time since transplants, daily dose, and number of co-medications administered.

Keywords: kidney transplant patients, tacrolimus, adherence

[1] Campagne, O., Mager, D. E., & Tornatore, K. M. (2019). Population pharmacokinetics of tacrolimus in transplant recipients: What did we learn about sources of interindividual variabilities? Journal of Clinical Pharmacology, 59(3), 309–325. https://doi.org/10.1002/jcph.1325

[2] Jing, Y., Kong, Y., Hou, X., Liu, H., Fu, Q., Jiao, Z., Peng, H., & Wei, X. (2021). Population pharmacokinetic analysis and dosing guidelines for tacrolimus co-administration with Wuzhi capsule in Chinese renal transplant recipients. Journal of Clinical Pharmacy and Therapeutics, 46(4), 1117– 1128. https://doi.org/10.1111/jcpt.13407

[3] Tornatore, K. M., Meaney, C. J., Attwood, K., Brazeau, D. A., Wilding, G. E., Consiglio, J. D., Gundroo, A., Chang, S. S., Gray, V., Cooper, L. M., & Venuto, R. C. (2022). Race and sex associations with tacrolimus pharmacokinetics in stable kidney transplant recipients. Pharmacotherapy, 42(2), 94– 105. https://doi.org/10.1002/phar.2656

[4] Chen, L., & Prasad, G. R. (2018). CYP3A5 polymorphisms in renal transplant recipients: Influence on tacrolimus treatment. Pharmacogenomics and Personalized Medicine, 11, 23–33. https://doi.org/10. 2147/PGPM.S107710

[5] Ortega Suárez, F. J., Sánchez Plumed, J., Pérez Valentín, M. A., Pereira Palomo, P., Mu noz Cepeda, M. A., Lorenzo Aguiar, D., & Grupo de Estudio VATREN. (2011). Validación del cuestionario simplificado de adherencia a la medicación (SMAQ) en pacientes con trasplante renal en terapia con tacrolimus [Validation on the simplified medication adherence questionnaire (SMAQ) in renal transplant patients on tacrolimus]. Nefrología, 31(6). https://doi. org/10.3265/Nefrologia.pre2011.Aug.10973

[6] Lehner, L. J., Reinke, P., Hörstrup, J. H., Rath, T., Suwelack, B., Krämer, B. K., Budde, K., & Banas, B. (2018). Evaluation of adherence and tolerability of prolonged-release tacrolimus (Advagraf TM ) in kidney transplant patients in Germany: A multicenter, noninterventional study. Clinical Transplantation, 32(1), e13142. https://doi.org/10.1111/ctr.13142

[7] Chisholm-Burns, M., Pinsky, B., Parker, G., Johnson, P., Arcona, S., Buzinec, P., Chakravarti, P., Good, M., & Cooper, M. (2012). Factors related to immunosuppressant medication adherence in renal transplant recipients. Clinical Transplantation, 26(5), 706–713. https://doi.org/10.1111/j.1399-0012.2011.01589.x

[8] Cossart, A. R., Cottrell, W. N., Campbell, S. B., Isbel, N. M., & Staatz, C. E. (2019). Characterizing the pharmacokinetics and pharmacodynamics of immunosuppressant medicines and patient outcomes in elderly renal transplant patients. Translational Andrology and Urology, 8(Suppl 2), S198– S213. https://doi.org/10.21037/tau.2018.10.16

[9] Tanriover, B., Stone, P. W., Mohan, S., Cohen, D. J., & Gaston, R. S. (2013, July). Future of Medicare immunosuppressive drug coverage for kidney transplant recipients in the United States. Clinical Journal of the American Society of Nephrology; CJASN, 8(7), 1258–1266. https://doi.org/10.2215/CJN.09440912

[10] Lalić, J., Veličković-Radovanović, R., Mitić, B., Paunović, G., & Cvetković, T. (2014). Immunosuppressive medication adherence in kidney transplant patients. Medical Principles and Practice, 23(4), 351– 356. https://doi.org/10.1159/000362792

[11] Abbas, A. A., Ahmed, M. E., Mohammed, S. M. E., Gar-Alnabi, S. S., Mohammed, W. A., Ahmed, M. H., & Badi, S. (2022). Adherence to immunosuppressive medications in kidney transplant patients at three centers in Khartoum state, Sudan: A cross-sectional hospital study. Sudan Journal of Medical Science, 17(3), 313–329. https://doi.org/10.18502/sjms.v17i3.12085

[12] Chen, T., Wang, Y., Tian, D., Zhang, J., Xu, Q., Lv, Q., Li, X., & Wang, J. (2022). Follow-up factors contribute to immunosuppressant adherence in kidney transplant recipients. Patient Preference and Adherence, 16, 2811–2819. https://doi.org/10.2147/PPA.S383243

[13] Terebelo, S., & Markell, M. (2010). Preferential adherence to immunosuppressive over nonimmunosuppressive medications in kidney transplant recipients. Transplantation Proceedings, 42(9), 3578–3585. https://doi.org/10.1016/j.transproceed.2010.08.027

[14] Prihodova, L., Nagyova, I., Rosenberger, J., Majernikova, M., Roland, R., Groothoff, J. W., & van Dijk, J. P. (2014). Adherence in patients in the first year after kidney transplantation and its impact on graft loss and mortality: A cross-sectional and prospective study. Journal of Advanced Nursing, 70(12), 2871–2883. https://doi.org/10.1111/jan.12447

[15] Denhaerynck, K., Dobbels, F., Cleemput, I., Desmyttere, A., Schäfer-Keller, P., Schaub, S., & De Geest, S. (2005). Prevalence, consequences, and determinants of nonadherence in adult renal transplant patients: A literature review. Transplant International, 18(10), 1121–1133. https://doi.org/10.1111/j.1432- 2277.2005.00176.x

[16] Massey, E. K., Tielen, M., Laging, M., Beck, D. K., Khemai, R., van Gelder, T., & Weimar, W. (2013). The role of goal cognitions, illness perceptions and treatment beliefs in self-reported adherence after kidney transplantation: A cohort study. Journal of Psychosomatic Research, 75(3), 229–234. https://doi.org/10.1016/j.jpsychores.2013.07.006

[17] Gheith, O. A., El-Saadany, S. A., Abuo Donia, S. A., & Salem, Y. M. (2008). Compliance of kidney transplant patients to the recommended lifestyle behaviours: Single centre experience. International Journal of Nursing Practice, 14(5), 398–407. https://doi.org/10.1111/j.1440-172X.2008.00710.x

[18] Tecen-Yucel, K., Bayraktar-Ekincioglu, A., Yildirim, T., Demirkan, K., & Erdem, Y. (2023). Assessment of adherence to immunosuppressive treatment in kidney transplant patients: A descriptive study. Turkish Journal of Nephrology, 32(3), 241–248. https://doi.org/10.5152/turkjnephrol.2023.21157239

[19] Griva, K., Davenport, A., Harrison, M., & Newman, S. P. (2012). Non-adherence to immunosuppressive medications in kidney transplantation: Intent vs. forgetfulness and clinical markers of medication intake. Annals of Behavioral Medicine: A Publication of the Society of Behavioral Medicine, 44(1), 85–93. https://doi.org/10.1007/s12160-012-9359-4

[20] Kuptsov, V. V. (1978). [Aspects of the public health management of a rural district]. Sovetskoe Zdravookhranenie, 7, 49–54.

[21] Russell, C. L., Cetingok, M., Hamburger, K. Q., Owens, S., Thompson, D., Hathaway, D., Winsett, R. P., Conn, V. S., Madsen, R., Sitler, L., & Wakefield, M. R. (2010). Medication adherence in older renal transplant recipients. Clinical Nursing Research, 19(2), 95–112. https://doi.org/10.1177/1054773810362039

[22] Tielen, M., van Exel, J., Laging, M., Beck, D. K., Khemai, R., van Gelder, T., Betjes, M. G., Weimar, W., & Massey, E. K. (2014). Attitudes to medication after kidney transplantation and their association with medication adherence and graft survival: A 2-year follow-up study. Journal of Transplantation, 2014, 675301. https://doi.org/10.1155/2014/675301

[23] Chisholm, M. A., Vollenweider, L. J., Mulloy, L. L., Jagadeesan, M., Wynn, J. J., Rogers, H. E., Wade, W. E., & DiPiro, J. T. (2000). Renal transplant patient compliance with free immunosuppressive medications. Transplantation, 70(8), 1240– 1244. https://doi.org/10.1097/00007890-200010270- 00020

[24] Nevins, T. E., Robiner, W. N., & Thomas, W. (2014). Predictive patterns of early medication adherence in renal transplantation. Transplantation, 98(8), 878– 884. https://doi.org/10.1097/TP.0000000000000148

[25] Henkel, L., Jehn, U., Thölking, G., & Reuter, S. (2023). Tacrolimus-why pharmacokinetics matter in the clinic. Frontiers in Transplantation, 2, 1160752. https://doi.org/10.3389/frtra.2023.1160752

[26] Chauhan, P. M., Hemani, R. J., Solanki, N. D., Shete, N. B., Gang, S. D., Konnur, A. M., Srivastava, R., & Pandey, S. N. (2023). A systematic review and metaanalysis recite the efficacy of tacrolimus treatment in renal transplant patients in association with genetic variants of CYP3A5 gene. American Journal of Clinical and Experimental Urology, 11(4), 275–292.

[27] Kuypers, D. R. J. (2020). Intrapatient variability of tacrolimus exposure in solid organ transplantation: A novel marker for clinical outcome. Clinical Pharmacology and Therapeutics, 107(2), 347–358. https://doi.org/10.1002/cpt.1618